IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy.
Klinikum Bremen-Mitte, Professor Hess Children's Hospital, Bremen, Germany.
Blood Rev. 2021 Nov;50:100833. doi: 10.1016/j.blre.2021.100833. Epub 2021 Apr 27.
Factor X deficiency is a rare coagulation disorder that can be hereditary or acquired. The typology and severity of the associated bleeding symptoms are highly heterogeneous, adding to the difficulties of diagnosis and management. Evidence-based guidelines and reviews on factor X deficiency are generally limited to publications covering a range of rare bleeding disorders. Here we provide a comprehensive review of the literature on factor X deficiency, focusing on the hereditary form, and discuss the evolution in disease management and the evidence associated with available treatment options. Current recommendations advise clinicians to use single-factor replacement therapy for hereditary disease rather than multifactor therapies such as fresh frozen plasma, cryoprecipitate, and prothrombin complex concentrates. Consensus in treatment guidelines is still urgently needed to ensure optimal management of patients with factor X deficiency across the spectrum of disease severity.
因子 X 缺乏症是一种罕见的凝血障碍,可分为遗传性或获得性。相关出血症状的类型和严重程度高度异质,这增加了诊断和管理的难度。基于证据的因子 X 缺乏症指南和综述通常仅限于涵盖一系列罕见出血性疾病的出版物。在这里,我们提供了因子 X 缺乏症文献的全面综述,重点介绍遗传性形式,并讨论疾病管理方面的演变以及与现有治疗选择相关的证据。目前的建议建议临床医生对遗传性疾病使用单因子替代疗法,而不是使用新鲜冷冻血浆、冷沉淀和凝血酶原复合物浓缩物等多因子疗法。仍然迫切需要在治疗指南方面达成共识,以确保在整个疾病严重程度范围内对因子 X 缺乏症患者进行最佳管理。